Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Edwards Lifesciences (EW) a Great Value Stock Right Now?

Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 stock picks which helped them beat the market by nearly 16 percentage points. There weren’t a lot of funds who could deliver these kinds of returns without shorting the market or using aggressive put options.

In the said letter, Artisan Mid Cap Fund highlighted a few stocks and Edwards Lifesciences Corp (NYSE:EW) is one of them. Edwards Lifesciences is a medical technology company based in California. Year-to-date, EW stock lost 4.4% and on May 8th it had a closing price of $217.84. Its market cap is of $46.1 billion. Here is what Artisan Mid Cap Fund said:

“Edwards Lifesciences is the leader in transcatheter aortic valve replacements (TAVR)—one of the fastest-growing, large medical device markets globally. While we believe the company will experience further momentum in the US and European TAVR markets, other parts of the company’s business are facing headwinds. Clinical trials for the company’s transcatheter mitral and tricuspid therapies have been pushed out as hospitals focus on COVID-19, there is little margin expansion expected in 2020, and there is uncertainty surrounding the potential costs from a pending intellectual property lawsuit related to its PASCAL valve. Given these headwinds, its relatively high valuation, and with the market cap outgrowing our mid-cap mandate, we exited our position.”

In Q4 2019, the number of bullish hedge fund positions on EW stock increased by about 25% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with EW’s potential growth concerns.

Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.